As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
8don MSN
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Investor's Business Daily on MSN9d
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered StockThe Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Cystic fibrosis, a genetic disease that attacks the lungs, affects roughly 1 in 3,000 people, and cystic fibrosis-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback